AUA 2018 - Results from #320

Viewing 321-340 of 364 articles

AUA 2018: Prostate Cancer Tumor Board

AUA 2018: Health-Related Quality of Life in Patients with mCRPC Treated with Cabazitaxel, CAPRISTANA

AUA 2018: Neoadjuvant Enzalutamide and ADT in High-Risk Prostate Cancer: Initial Imaging and Surgical Findings from a Phase II Clinical Trial

AUA 2018: Clinical Experience with Lutetium 177-labeled PSMA-I&T for Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer

AUA 2018: Other Malignancies prior Prostate Cancer Diagnosis – Clinical Outcome after Radical Prostatectomy

AUA 2018: Predictors of Radiographic Progression in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone: Retrospective Analysis of COU-AA-302

AUA 2018: The Impact of Prior Local Therapy on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer: Results from SEARCH

AUA 2018: Oophorectomy at Time of Radical Cystectomy: Re-evaluating the Definition of Radical Cystectomy in Women

AUA 2018: Assessing the Under-Estimation of Nodal Tumour Burden by 68ga-PSMA and 11c-Choline PET/CT Scan in Patients Treated with Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer

AUA 2018: Radical Cystectomy Provides Improved Survival Outcomes and Decreased Costs Compared with Trimodal Therapy for Patients Diagnosed with Localized Muscle-Invasive Bladder Cancer

AUA 2018: Phase 3 Study of Intermittent Monotherapy Versus Continuous Combined Androgen Deprivation

AUA 2018: Comprehensive Characterization of Returns to the Operating Room following Radical Cystectomy

AUA 2018: Results from SPARTAN: PSA Outcomes in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide

AUA 2018: The PROSPER Trial: Chemotherapy-related Endpoints in Patients with Nonmetastatic Castration-resistant Prostate Cancer Treated with Enzalutamide

AUA 2018: Crossfire Debate: Controversies in Prostate Cancer (Con) – ADT plus Abiraterone is Key to Prolonging Survival in Oligometastatic Prostate Cancer

AUA 2018: A Crossfire Debate: Controversies in Prostate Cancer (Pro) – Focal Ablation of Oligometastatic Prostate Cancer

AUA 2018: Impact of Post-Treatment Psychiatric Illness on Survival Outcomes Following Treatment for Patients with Muscle-Invasive Bladder Cancer

AUA 2018: Perioperative Blood Transfusion is Not an Independent Predictor of Survival After Radical Cystectomy

AUA 2018: The Impact of Agent Orange Exposure on Bladder Cancer

AUA 2018: Tumor Board - Bladder Cancer: Treatment Algorithms for Localized Bladder Cancer

10
11
12
13
14
15
16
17
18
19